Rahul Banerjee: My top 10 ASCO 24 multiple myeloma abstracts
Rahul Banerjee, Assistant Professor in the Division of Medical Oncology at the University of Washington, shared on X:
“Huge thanks to Mike Thompson for keeping track of myeloma abstracts each year!
My top 10 ASCO 24 MMsm abstracts:
Abstract #7501 (Leleu et al): IFM 2020-05.
Isa-VRd (1x wkly Velcade 👏) beat Isa-Rd in ASCT-ineligible MM.
Quads for all? (See next tweet)
Abstract #7500 (Facon et al): IMROZ. Isa-VRd beat VRd in ASCT-ineligible.
Our quad vs triplet pathway for NDMM is more & more irrelevant.
Dynamic frailty real, and ⬆️ PFS meaningful – quad worth trying in some such pts!
Abstract 7510 (Nizar Jacques Bahlis et al): More insights from CANOVA: Ven-dex vs Pd in t(11;14) MM.
– BCL2 (RNAseq, not IHC): Ven-dex again wins if ⬆️.
– Gain(1q) + t(11;14) NBD, but amp(1q) + t(11;14) did poorly no matter what
Abstract 7503 (Marivi Mateos et al): DREAMM-7 updates.
Even in HR cytogenetics, Bela-Vd beat D-Vd: mPFS 33.2 vs 10.5 mo. Anecdotally, responses often maintained even with belantamab holds.
Hopefully getting (re-)approved soon!
Abstract 7504 (Luciano J Costa et al): CARTITUDE-4 in functional high-risk MM, i.e. relapse ≤18 mo of treatment initiation.
12-mo PFS only 49% with SOC vs 77% with cilta-cel.
Here’s where I’ll prioritize 2nd-line CAR-T!
Abstract 7519 (Mahmoud Gaballa et al): Multicenter analysis of BCMA CAR-T if CNS involvement.
27% (3/11) ICANS (all ≤Gr3), ORR 73%, 100% CNS clearance.
Similar to lymsm: CNS involvement should change little in calculus!
Abstract 7517 (van de Donk et al): Updated data with prophylactic toci with teclistamab.
Only 25% of patients got CRS! 🤯 If PPx toci x1 becomes the norm, perhaps outpatient dosing the default and even no REMS some day??
Abstract 7536 (Carlyn Tan et al): Teclistamab de-escalation (I have a similar EHA2024 poster).
Keeping tec weekly until ≥6 months of sCR neither necessary nor realistic. 94% PFS after de-escalation (~3 months out)!
Abstract 7570 (Also Carlyn Tan et al, congrats!): Dara retreatment in CD38-refractory MM.
Provocative conclusion: ≥6 month washout has no impact on ORR.
Might ex vivo testing (cc Daniel Sherbenou) be the future?
Abstract #7525 (Kim et al): Renal recovery with inpatient dara for acute cast nephropathy.
Median time to ≥50% LC reduction with 🏥 dara (e.g. D-CyBorD) only 3 days.
Inpatient dara cheaper & easier than PLEX, right??
Many excellent abstracts I accidentally missed, sorry!
+ shout-out to my Fred Hutchinson Cancer Center colleage Chris Su for poster #11085.
Financial fragility in MMsm worsens outcomes. Not the same as FinTox… novel tools needed!
And adding some of the many co-authors for the 10 ASCO24 MMsm abstracts above: Noopur Raje, Andrew Yee, Saad Z. Usmani, Urvi Shah, Malin Hultcrantz, Sridevi Rajeeve, Krina Patel, Robert Z. Orlowski, Tom Martin, Meral Beksac, Rakesh Popat, Surbhi Sidana, Thanos Dimopoulos and more!”
Source: Rahul Banerjee/X